Moleculin Biotech receives Nasdaq delisting notice; bid price below $1 for 30 days

Moleculin Biotech, Inc.

Nasdaq notified Moleculin on Sept 15, 2026 that common stock failed minimum bid price ($1) from July 31 to Sept 11, 2026.
Company ineligible for 180-day cure period due to 1-for-25 reverse stock split effected Dec 1, 2025.
Company will request a hearing before Nasdaq Hearings Panel; trading continues pending panel decision.
No assurance of continued listing; risk of suspension or delisting if hearing fails.

Featured in Daily 8-K Digest

Selected #2 for 2026-09-18. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.